Revolution Medicines focuses on developing targeted therapies for cancer treatment. The company is self-described as being 'on target' to outsmart cancer.

Revolution Medicines

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

COM:REVMED

Revolution Medicines

Last Close

57.07

21/11 21:00

Market Cap

9.55B

Beta: -

Volume Today

864.68K

Avg: -

Filings Not Available